Brainstorm Cell Therapeutics Inc (BCLI)

$0.26

-0.02

(-7.04%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $0.25
    $0.28
    $0.26
    downward going graph

    3.77%

    Downside

    Day's Volatility :10.64%

    Upside

    7.14%

    downward going graph
  • $0.13
    $1.51
    $0.26
    downward going graph

    48.46%

    Downside

    52 Weeks Volatility :91.13%

    Upside

    82.78%

    downward going graph

Returns

PeriodBrainstorm Cell Therapeutics IncIndex (Russel 2000)
3 Months
-37.36%
0.0%
6 Months
-25.98%
0.0%
1 Year
-82.24%
0.0%
3 Years
-92.45%
-22.3%

Highlights

Market Capitalization
22.6M
Book Value
- $0.04
Earnings Per Share (EPS)
-0.2
PEG Ratio
0.0
Wall Street Target Price
3.46
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-178.2%
Return On Equity TTM
-1121.9%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-16.0M
Diluted Eps TTM
-0.2
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.18
EPS Estimate Next Year
-0.22
EPS Estimate Current Quarter
-0.03
EPS Estimate Next Quarter
-0.03

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Brainstorm Cell Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 1230.77%

Current $0.26
Target $3.46

Technicals Summary

Sell

Neutral

Buy

Brainstorm Cell Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Brainstorm Cell Therapeutics Inc
Brainstorm Cell Therapeutics Inc
-6.33%
-25.98%
-82.24%
-92.45%
-93.59%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.97%
16.25%
37.11%
69.18%
305.56%
Novo Nordisk A/s
Novo Nordisk A/s
9.99%
-3.52%
34.24%
158.74%
417.73%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-5.15%
64.67%
22.72%
31.08%
198.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
14.0%
36.06%
143.5%
167.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Brainstorm Cell Therapeutics Inc
Brainstorm Cell Therapeutics Inc
NA
NA
0.0
-0.18
-11.22
-1.78
NA
-0.04
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
44.01
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Brainstorm Cell Therapeutics Inc
Brainstorm Cell Therapeutics Inc
Sell
$22.6M
-93.59%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
305.56%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$585.3B
417.73%
44.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
198.44%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
167.72%
32.84
-4.74%

Insights on Brainstorm Cell Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, -569.0K → 365.0K (in $), with an average increase of 255.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -3.40M → -2.54M (in $), with an average increase of 33.8% per quarter

  • Vs REGN

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 119.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 161.6%

Institutional Holdings

  • Armistice Capital, LLC

    9.93%

  • Vanguard Group Inc

    1.89%

  • BlackRock Inc

    0.48%

  • Geode Capital Management, LLC

    0.45%

  • Liberty Wealth Management, LLC

    0.43%

  • Weaver Consulting Group

    0.29%

Company Information

brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr

Organization
Brainstorm Cell Therapeutics Inc
Employees
29
CEO
Mr. Chaim Lebovits
Industry
Electronic Technology

Discover More

FAQs